Drug Information

Drug General Information
Drug ID
D0N1BF
Former ID
DIB008739
Drug Name
LY-2811376
Drug Type
Small molecular drug
Indication Alzheimer disease [ICD9: 331; ICD10:G30] Phase 1 [522571], [541979]
Company
Eli Lilly & Co
Formula
C15H14F2N4S
InChI
InChI=1S/C15H14F2N4S/c1-15(2-3-22-14(18)21-15)11-4-10(12(16)5-13(11)17)9-6-19-8-20-7-9/h4-8H,2-3H2,1H3,(H2,18,21)/t15-/m0/s1
InChIKey
MJQMRGWYPNIERM-HNNXBMFYSA-N
PubChem Compound ID
44251605
PubChem Substance ID
85286240, 89983742, 99437206, 103924885, 137986191, 140419282, 144116165, 144236995, 160828708, 162011703, 162205125, 163093680, 163390266, 163620704, 163686021, 163842305, 164135005, 164193941, 172086121, 174006688, 174526511, 178103518, 184816523, 188899592, 204429761, 223378259, 223621253, 223705125, 224326043, 227634630, 242586937, 247529799, 249730473, 249807610, 249855753, 250200952, 251910650, 251963140, 252069907, 252109923, 252160837, 252444081, 252451578
Target and Pathway
Target(s) Beta-secretase Target Info Inhibitor [531702], [551187]
References
Ref 522571ClinicalTrials.gov (NCT00838084) A Safety Study of LY2811376 Single Doses in Healthy Subjects. U.S. National Institutes of Health.
Ref 541979(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6936).
Ref 531702Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci. 2011 Nov 16;31(46):16507-16.
Ref 551187Neurodegenerative disease: Inhibiting beta-secretase in humans. Nature Reviews Drug Discovery 11, 21 (January 2012).